Literature DB >> 18438866

Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels.

H van Dekken1, R van Marion, K J Vissers, W C J Hop, W N M Dinjens, H W Tilanus, J C Wink, M van Duin.   

Abstract

Amplification of chromosome band 7q21 has been frequently detected in various types of cancer including gastroesophageal junction (GEJ) adenocarcinomas. At present, no gene has been disclosed that can explain this frequent amplification of 7q21 in GEJ carcinomas. Therefore, a detailed genomic analysis of the 7q21 region was performed on a selected series of GEJ adenocarcinomas, i.e., 14 primary adenocarcinomas and 10 cell lines, by array comparative genomic hybridization (aCGH) with a 7q11.22-q31.2 contig array. A distinct peak of amplification was identified at 92.1 Mb in 7q21.2, precisely comprising cyclin-dependent kinase 6 (CDK6), a gene involved in cell cycle regulation. A smaller peak was seen at 116.2 Mb in 7q31.2, the locus of the MET proto-oncogene. No distinct peak was detected for the hepatocyte growth factor (HGF) at 81.3 Mb in 7q21.11. An immunoprofile of HGF, CDK6 and MET revealed a strong correlation between aCGH and immunohistochemical protein expression for CDK6 (P = 0.002). Furthermore, immunohistochemistry did not show expression of CDK6 in Barrett's dysplasia and carcinoma in situ, correlating expression of CDK6 with a malignant phenotype. We conclude that high-resolution genomic analysis and immunoprofiling identify CDK6 as the main candidate target for the recurrent amplification of 7q21 in GEJ adenocarcinomas. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438866     DOI: 10.1002/gcc.20570

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

Review 1.  Clinical impact of aneuploidy on gastric cancer patients.

Authors:  Isabel Sánchez-Pérez; Pilar García Alonso; Cristóbal Belda Iniesta
Journal:  Clin Transl Oncol       Date:  2009-08       Impact factor: 3.405

2.  Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma.

Authors:  Amin Ismail; Santhoshi Bandla; Marie Reveiller; Liana Toia; Zhongren Zhou; William E Gooding; Irina Kalatskaya; Lincoln Stein; Mary D'Souza; Virginia R Litle; Jeffrey H Peters; Arjun Pennathur; James D Luketich; Tony E Godfrey
Journal:  Clin Cancer Res       Date:  2011-05-18       Impact factor: 12.531

3.  Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.

Authors:  Meng Chen; Yuanqing Ye; Hushan Yang; Pheroze Tamboli; Surena Matin; Nizar M Tannir; Christopher G Wood; Jian Gu; Xifeng Wu
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

4.  Integrated molecular analysis reveals complex interactions between genomic and epigenomic alterations in esophageal adenocarcinomas.

Authors:  DunFa Peng; Yan Guo; Heidi Chen; Shilin Zhao; Kay Washington; TianLing Hu; Yu Shyr; Wael El-Rifai
Journal:  Sci Rep       Date:  2017-01-19       Impact factor: 4.379

5.  MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6.

Authors:  Shu-Mei Chen; Hua-Chien Chen; Shu-Jen Chen; Chiung-Yin Huang; Pin-Yuan Chen; Tai-Wei Erich Wu; Ly-Ying Feng; Hong-Chieh Tsai; Tai-Ngar Lui; Chuen Hsueh; Kuo-Chen Wei
Journal:  World J Surg Oncol       Date:  2013-04-17       Impact factor: 2.754

6.  Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.

Authors:  Nikolai V Litviakov; Nadezhda V Cherdyntseva; Matvey M Tsyganov; Elena M Slonimskaya; Marina K Ibragimova; Polina V Kazantseva; Julia Kzhyshkowska; Eugeniy L Choinzonov
Journal:  Oncotarget       Date:  2016-02-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.